跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 3,104 条关于
“EP300/CBP”
全部
3,104
临床试验
2,254
药物
568
机构
16
资讯
266
2年前
Opna Bio Initiates Phase I Trial of OPN-6602 for Multiple Myeloma
9个月前
Opna Bio's Zavabresib Receives FDA Orphan Drug Designation for Myelofibrosis Treatment
去年
Foghorn Therapeutics Advances Oncology Programs Targeting Chromatin Dysregulation
8个月前
Foghorn Therapeutics Secures $50 Million Financing to Advance First-in-Class Cancer Pipeline
去年
Pathos AI Initiates Phase 1b/2a Trial of Pocenbrodib for Metastatic Castration-Resistant Prostate Cancer
11个月前
Foghorn Therapeutics Reports Breakthrough Progress in Selective ARID1B Degrader for Cancer Treatment
10个月前
Foghorn Therapeutics Advances Multi-Target Protein Degrader Pipeline with FHD-909 Phase 1 Trial Progressing
去年
FDA Grants Orphan Drug Designation to OPN-6602 for Relapsed/Refractory Multiple Myeloma Treatment
去年
First-in-Class CBP/p300 Inhibitor TT125-802 Shows Promise in Treatment-Resistant NSCLC
去年
Coherent Biopharma's CBP-1008 Receives FDA Fast Track Designation for Platinum-Resistant Ovarian Clear Cell Carcinoma
第 1 页,共 27 页
上一页
下一页